Simplified Chinese
scroll down
Bringing in advanced technologies
Minhai Biologics is the only Chinese company that maintains in-depth collaborations with the four global vaccine industry leaders: Merck of the United States, Sanofi of France, AstraZeneca of the United Kingdom, and INTRAVACC of the Netherlands.
The company places great emphasis on introducing cutting-edge international technologies, enriching its technological portfolio and reserves, and, building on the integration and assimilation of these technologies, enhancing its capacity for independent innovation and accelerating the commercialization of its proprietary innovations.
In April 2023, a cooperation agreement was signed with Indonesia’s Biotis Company—marking the world’s first dual‑carrier 13‑valent pneumococcal vaccine to undergo technology transfer to Indonesia.
In March 2023, a signing ceremony was held at the Boao Forum for Asia with AstraZeneca and Indonesia’s Combiphar.
In August 2022, a signing ceremony was held with Phil. Pharmawealth Inc., the Philippines’ largest importer of injectable pharmaceuticals.
In July 2021, a framework agreement on vaccine project cooperation was signed with DESMONS CONSULTINGSPRL of Belgium.
In May 2021, a cooperation agreement was signed with AMSISA/University of Chile.
2020 United Kingdom–AstraZeneca COVID-19 vaccine
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account
0
%